Exenatide

Byetta/BydureonMetabolic/Weight

Evidence grade

AFDA-approved Rx (labeled use)

Cardiovascular · 0–5 · separate axis

PurposeMetabolic / Diabetes

MechanismGLP-1 receptor agonist: improves insulin secretion and satiety

EffectsLess hunger, slower digestion, better blood sugar; often improves BP and overall CV risk

DosingNo human dose established.

Bottom lineStrongest data when used for its labeled indication under clinician guidance.

Batches on filenone

No tested batches on file.

Read with10

Glucagon Tesamorelin Somatropin Sermorelin CJC-1295 (no DAC)Ipamorelin GHRP-2 GHRP-6 BPC-157 TB-500

Cautions & interactions

GI effects; pancreatitis; renal considerations

Caution with insulin/sulfonylureas (hypoglycemia risk); delays gastric emptying may affect absorption of oral meds; monitor for dehydration if on diuretics.

CV 5 of 5 — Strong human outcomes data via diabetes/obesity trials; improves multiple CV risk factors (weight, glucose, BP).